Irbesartan

CHEMBL1513 Phase 4 Одобрено Small molecule
Half-Life
11-15 hours
Bioavailability
Protein Binding
Molecular Weight
428.5 g/mol
LogP
4.1
Phase
4

This angiotensin II receptor blocker (ARB) is used to treat high blood pressure, heart failure, and kidney disease in patients with type 2 diabetes. It works by blocking the AT1 receptor for angiotensin II, causing blood vessels to relax and reducing aldosterone secretion. It is often used in patients who cannot tolerate ACE inhibitors due to cough.

Молекулярная масса

428,5320 g/mol

LogP

4,10

TPSA

87,10 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Классы препаратов

Механизм действия

Selective non-competitive angiotensin II type 1 receptor antagonist.

Pharmacokinetics (PK)

Half-Life 11-15 hours

Pharmacodynamics (PD)

Механизм

Selective non-competitive angiotensin II type 1 receptor antagonist.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1

InChI

InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

Molecular Formula

C25H28N6O

HBD / HBA

1 / 5

Вращаемые Связи

7

Тяжёлые Атомы

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

This angiotensin II receptor blocker (ARB) is used to treat high blood pressure, heart failure, and kidney disease in patients with type 2 diabetes. It works by blocking the AT1 receptor for angiotensin II, causing blood vessels to relax and reducing aldosterone secretion. It is often used in patients who cannot tolerate ACE inhibitors due to cough.

Selective non-competitive angiotensin II type 1 receptor antagonist.

Key pharmacokinetic parameters for Irbesartan: Half-life: 11-15 hours.

Yes, Irbesartan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1513. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3749. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.